Flinn, I. W., Burke, J. M., Tun, A. M., Ayed, A., Biondo, J. M. L., Wu, M., Hossain, F., Mun, Y., Farighi, R., Singh, A., Misleh, J., Peles, S., Budde, L. E., Villasboas, J. C., Sharman, J. P. (2026). Fixed-duration subcutaneous (SC) mosunetuzumab (Mosun) in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Interim analysis and patient-reported outcomes (PROs) from the phase 2 MorningSun study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7029